News
BCRX
10.82
+2.27%
0.24
BRIEF-Biocryst Presents New Data Demonstrating Consistently Low Attack Rates Among Hae Patients After Switching To Orladeyo (Berotralstat)
BRIEF-Biocryst Presents New Data Demonstrating Consistently Low Attack Rates Among Hae Patients After Switching To Orladeyo (Berotralstat)
Reuters · 17h ago
Here's What BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shareholder Ownership Structure Looks Like
A look at the shareholders of BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) can tell us which group is most powerful...
Simply Wall St. · 06/23 11:00
BRIEF-BioCryst Announces Orladeyo Data To Be Presented At EAACI Hybrid Congress 2022
BRIEF-BioCryst Announces Orladeyo Data To Be Presented At EAACI Hybrid Congress 2022
Reuters · 06/22 11:19
BioCryst Announces ORLADEYO® (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022
RESEARCH TRIANGLE PARK, N.C., June 22, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced multiple upcoming data presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022 from ...
GlobeNewswire · 06/22 11:00
Strength Seen in BioCryst (BCRX): Can Its 5.5% Jump Turn into More Strength?
BioCryst (BCRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks · 06/20 12:26
Durham pharma gets another boost with FDA fast-track designation
After securing a place in a European program designed to accelerate the process of getting medicines to patients with unmet medical needs, a Durham-based pharmaceutical company has landed a spot in a similar U.S. program. BioCryst Pharmaceuticals (Nasdaq:...
American City Business Journals · 06/10 18:09
BRIEF-BioCryst Selects Pint Pharma As Commercial Partner For Orladeyo Berotralstat In Latin America
reuters.com · 06/09 11:38
BioCryst collaborates with Pint Pharma to sell Orladeyo in Latin America
BioCryst Pharmaceuticals (NASDAQ:BCRX) said it entered an exclusive collaboration with Austria-based Pint Pharma to register and promote its hereditary angioedema attack (HAE) prevention therapy Orladeyo in the pan-Latin America (LATAM) region. HAE is a di...
Seekingalpha · 06/09 11:25
BioCryst Selects Pint Pharma As Commercial Partner For ORLADEYO In Latin America
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into an exclusive collaboration with Pint Pharma GmbH to register and promote ORLADEYO® (berotralstat) in the pan-Latin
Benzinga · 06/09 11:01
BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO® (berotralstat) in Latin America
RESEARCH TRIANGLE PARK, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into an exclusive collaboration with Pint Pharma GmbH to register and promote ORLADEYO® (berotralstat) in ...
GlobeNewswire · 06/09 11:00
BioCryst Pharmaceuticals Taps Pint Pharma as Commercial Partner for Orladeyo Drug in Latin America
MT Newswires · 06/09 07:34
BioCryst Gets FDA Fast Track Designation For Bone Formation Disorder Candidate
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BioCryst Pharmaceuticals's (NASDAQ: BCRX) lead drug candidate BCX9250 for the prevention of heterotopic ossification (HO) in patients with fibrodysplasia ossificans progressi...
Benzinga · 06/08 14:14
BioCryst nabs FDA’s Fast Track status for candidate targeting rare bone forming disorder
Commercial-stage biotech BioCryst Pharmaceuticals (NASDAQ:BCRX) announced on Wednesday that the FDA granted Fast Track designation for BCX9250 to prevent heterotopic ossification (HO) in ultra-rare genetic disorder fibrodysplasia ossificans progressiva (FO...
Seekingalpha · 06/08 14:01
The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 06/08 13:07
BRIEF-FDA Grants Fast Track Designation For BioCryst's ALK-2 Inhibitor, BCX9250
reuters.com · 06/08 12:36
BioCryst's BCX9250 Secures Fast Track Designation from the US Food and Drug Administration
MT Newswires · 06/08 07:52
BRIEF-Biocryst Announces Approval Of Orladeyo By Swissmedic
reuters.com · 06/07 13:08
Biocryst Announces Approval Of ORLADEYO (berotralstat) By Swissmedic
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Swissmedic has granted marketing authorization for oral, once-daily ORLADEYO® (berotralstat) for the routine prevention of recurrent
Benzinga · 06/07 13:07
BioCryst Announces Approval of ORLADEYO® (berotralstat) by Swissmedic
RESEARCH TRIANGLE PARK, N.C., June 07, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Swissmedic has granted marketing authorization for oral, once-daily ORLADEYO® (berotralstat) for the routine prevention of re...
GlobeNewswire · 06/07 13:00
BioCryst Pharmaceuticals Says Swiss Drug Regulator Approves Orladeyo to Prevent Angioedema Attacks
MT Newswires · 06/07 10:20
More
Webull provides a variety of real-time BCRX stock news. You can receive the latest news about Biocryst Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About BCRX
BioCryst Pharmaceuticals, Inc. (BioCryst) is a commercial-stage biotechnology company that discovers small-molecule medicines. The Company focus on oral treatments for rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years and older. BioCryst has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 (ALK-2) inhibitor for the treatment of fibrodysplasia ossificans progressiva, and Galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza.